Spectrum's FUSILEV sNDA accepted by FDA for review

Spectrum Pharmaceuticals (NasdaqGM: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the complete response regarding its supplemental New Drug Application (sNDA) for FUSILEV^® (levoleucovorin) for Injection for treatment of patients with advanced metastatic colorectal cancer.

The FDA considers the submission a Class 2 response, therefore, the PDUFA Action Date is April 29, 2011.

FUSILEV is currently FDA approved and marketed by Spectrum for rescue after high-dose methotrexate therapy in osteosarcoma. FUSILEV is also indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination, and of inadvertent overdosage of folic acid antagonists.